Bruker AXS and Bruker Optics Introduce D8 SCREENLAB(TM), a Combined XRD and Raman High-Throughput Screening System for Advanced
13 March 2006 - 11:00PM
Business Wire
At Pittcon 2006, Bruker AXS Inc. today launches its new D8
SCREENLAB(TM), a screening system which combines the analytical
power of two-dimensional X-ray diffraction (XRD2) and Raman
spectroscopy. The D8 SCREENLAB integrates the Bruker AXS D8
DISCOVER XRD2 system for combinatorial materials screening with the
Bruker Optics Raman probe into one combined advanced materials
discovery solution. In the D8 SCREENLAB, the X-ray source, optics
and unique 2D X-ray detector, as well as the laser source, the
Raman probe and an auto-zoomed video microscope are all integrated
into one single platform. As a result, the X-ray diffraction
pattern, the Raman spectrum as well as the optical image from the
same sample can be obtained in one sample run from a materials
library. The powerful PolySNAP(TM) pattern matching software of the
D8 SCREENLAB allows the processing of XRD2 and Raman data, and
correlates the analysis results. Professor Chris Frampton, Chief
Scientific Officer for Pharmorphix Ltd., Cambridge, UK, states:
"Combinatorial discovery and optimization methods require rapid
screening to evaluate variations of composition, structure and
property within advanced materials libraries. While X-ray
diffraction provides information on the atomic arrangement in the
sample, Raman spectroscopy measures the characteristic vibration
frequencies determined by the chemical bonds. Both X-ray
diffraction and Raman spectroscopy are non-destructive methods that
require little or no sample preparation, thus allowing samples to
be analyzed simply and quickly in their natural form. A combined
instrument with both XRD and Raman capabilities is very beneficial
to high-throughput combinatorial screening in advanced materials
and catalyst discovery. In the pharmaceutical industry, screening
based on spectroscopic and diffraction techniques can be important
for drug formulations since the polymorphism of active ingredients
has to be controlled to achieve reliable product quality which will
satisfy regulatory authorities. The addition of Raman spectroscopy
provides even better discrimination in cases where the X-ray data
are ambiguous." Dr. Bob He, Director of R&D for Bruker AXS,
adds: "Scientists and engineers from both Bruker AXS and Bruker
Optics worked jointly to integrate the best technologies from the
two companies into this innovative systems solution. With the
combination of two analytical methods, the novel D8 SCREENLAB
allows our customers to explore new opportunities in advanced
materials research." Pittcon 2006, the 57th Pittsburgh Conference
and Exposition on Analytical Chemistry and Applied Spectroscopy, is
being held March 13-16 in Orlando, Florida in the Orange County
Convention Center. The D8 SCREENLAB will be exhibited at the Bruker
AXS booth, #3155. ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR) Bruker
BioSciences Corporation, headquartered in Billerica, Massachusetts,
is the publicly traded parent company of Bruker Daltonics Inc. and
Bruker AXS Inc. Bruker AXS is a leading developer and provider of
life science, materials research and industrial X-ray analysis
tools. Bruker Daltonics is a leading developer and provider of
innovative life science tools based on mass spectrometry. Bruker
Daltonics also offers a broad line of nuclear, biological and
chemical (NBC) detection products for defense and homeland
security. For more information, please visit
www.bruker-biosciences.com ABOUT BRUKER OPTICS Bruker Optics Inc is
a privately held company, which manufactures and distributes
analytical and process analysis instruments based on infrared,
near-infrared, Raman and TD-NMR spectroscopy. These products are
utilized in industry, government and academia for a wide range of
applications, such as chemical, polymer, forensic, and
pharmaceuticals. The company is based in Billerica, Massachusetts
and has manufacturing facilities in Ettlingen, Germany and The
Woodlands, Texas. For more information, please visit
http://www.brukeroptics.com CAUTIONARY STATEMENT OF BRUKER
BIOSCIENCES Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. The factors that could
cause actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company's reorganization strategies,
integration risks, failure of conditions, technological approaches,
product development, market acceptance, cost and pricing of the
Company's products, exposure to currency fluctuations, changes in
governmental regulations, capital spending and government funding
policies, FDA and other regulatory approvals to the extent
applicable, competition, the intellectual property of others,
patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the
SEC, including, without limitation, our respective annual reports
on Form 10-K, our most recent quarterly reports on Form 10-Q, and
our current reports on Form 8-K. We disclaim any intent or
obligation to update these forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024